SRAM
MYGN icon

Stone Ridge Asset Management’s Myriad Genetics MYGN Stock Holding History

Stone Ridge Asset Management’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-12,397
Closed -$426K – 1365
2017
Q4 		$426K Buy
+12,397
New +$418K 0.03% 884

Other funds holding MYGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Thrivent Financial for Lutherans
Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Stone Ridge Asset Management's MYGN Position: Q1 2018 in Review

Stone Ridge Asset Management sold out of Myriad Genetics (MYGN) in Q1 2018, closing a stake of 12,397 shares — an estimated $426K sold.

Stone Ridge Asset Management first reported a position in MYGN in Q4 2017 and held it in 1 quarter. The position peaked at $426K in Q4 2017. 260 funds tracked by Wall St. Rank hold MYGN as of Q1 2018.

  • Stone Ridge Asset Management reported no remaining Myriad Genetics position as of Q1 2018 after selling out during the quarter.
  • Stone Ridge Asset Management sold 12,397 Myriad Genetics shares in Q1 2018, an estimated $426K.
  • Stone Ridge Asset Management first reported a position in Myriad Genetics in Q4 2017 and held it in 1 quarter.
  • Stone Ridge Asset Management's Myriad Genetics position peaked at $426K in Q4 2017.
  • 260 funds tracked by Wall St. Rank held Myriad Genetics as of Q1 2018.

Based on Stone Ridge Asset Management's 13F filing for Q1 2018, filed 14 May 2018.